| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 20/12/2024 | 23:00 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 18/12/2024 | 23:15 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 13/12/2024 | 23:16 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 02/12/2024 | 23:25 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 26/11/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 21/11/2024 | 23:15 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 07/11/2024 | 23:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 07/11/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 31/10/2024 | 21:01 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 03/09/2024 | 23:00 | GlobeNewswire Inc. | Iovance Biotherapeutics to Present at Upcoming Conferences | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 08/08/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 29/07/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 28/06/2024 | 13:00 | GlobeNewswire Inc. | Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 24/05/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics to Present at Upcoming Conferences and Events | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 23/05/2024 | 23:00 | GlobeNewswire Inc. | Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 17/05/2024 | 23:15 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 09/05/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 01/05/2024 | 12:01 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 24/04/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 04/03/2024 | 12:30 | GlobeNewswire Inc. | Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 28/02/2024 | 22:01 | GlobeNewswire Inc. | Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 22/02/2024 | 14:45 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 21/02/2024 | 22:44 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 20/02/2024 | 12:30 | GlobeNewswire Inc. | Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 16/02/2024 | 21:38 | GlobeNewswire Inc. | Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024 | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 16/02/2024 | 21:19 | GlobeNewswire Inc. | Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 14/02/2024 | 12:16 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 28/12/2023 | 13:27 | IH Market News | Wall Street Highlights: Amazon to Introduce Ads on Prime Video, JD.com Raises Salaries in 2024, and More | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 27/12/2023 | 13:54 | Dow Jones News | Iovance Shares Fall Premarket As FDA Places Study On Hold After Patient Death | NASDAQ:IOVA | Iovance Biotherapeutics Inc |
| 27/12/2023 | 13:00 | GlobeNewswire Inc. | Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer | NASDAQ:IOVA | Iovance Biotherapeutics Inc |